PCSK9 and atherosclerosis: Clarifying these mechanisms could lead to novel therapeutic strategies that integrate PCSK9 inhibitors with lysosome-targeting therapies to optimize the treatment of atherosclerosis, metabolic disorders, and inflammatory CVDs [61,62].